Dr. Silverstone has a 35-year background in brain and pharmaceutical research. Dr. Silverstone has highly relevant expertise in international drug and IP development, digital mental health, regulatory matters, and has been involved in multiple health related start-up companies. He has previously served as the Senior Vice President, Medical and Scientific Affairs of Biovail, one of Canada’s largest publicly traded pharmaceutical companies, prior to its merger with Valeant Pharmaceutical International.
Dr. Silverstone received his MD at the University of London and spent three years as a research fellow at the University of Oxford. Dr. Silverstone’s research achievements have won several awards, and he has published over 120 peer-reviewed articles.